Jens-Ole Bock is a central figure in the European CRISPR landscape. As founder of CRISPR Medicine News (CMN), the CRISPRMED Conference series in Copenhagen, and the newly launched non-profit European Genomic Medicine Consortium (EGMEDC), he has spent more than two decades bridging the gap between breakthrough gene-editing science and clinical reality.
We sat down with Jens-Ole to discuss why 2026 is the year Medicon Valley must move from “innovation” to “infrastructure.”
What is the objective of CRISPR Medicine News?
CRISPR Medicine News was created to connect scientific innovation in genome editing with real clinical and societal impact. Our objective is to provide an open-access, high-quality news and intelligence platform focused on following CRISPR technologies from research through translation, regulation, and clinical application.
We aim to:
- Curate and contextualize global developments in CRISPR-based therapeutics
- Support informed decision-making across academia, biotech, pharma, healthcare systems, and policy
- Foster dialogue around clinical readiness, manufacturing, ethics, and patient access
At its core, our objective is to accelerate responsible CRISPR medicine development by ensuring that innovation is matched with clarity, collaboration, and credibility.
Why have you chosen to host the CRISPR Medicine Conference 2026 in Copenhagen?
Copenhagen is a natural choice because it sits at the center of one of Europe’s most integrated and mature life science ecosystems. The region combines world-leading research, strong clinical translation capabilities, and a collaborative public–private innovation model.
Equally important, Copenhagen and the surrounding Medicon Valley region represent a healthcare-driven approach to innovation, one where advanced therapies are developed with a clear line of sight to patients, health systems, and long-term societal value.
For a conference focused on moving CRISPR from promise to practice, Copenhagen provides both the scientific depth and the systemic perspective required.
How do you think Medicon Valley and the Nordics can contribute to the overall objective?
Medicon Valley Alliance and the broader Nordic region have a distinctive role to play in shaping the future of CRISPR medicine.
The region offers:
Deep integration between research institutions, hospitals, biotech, and pharma, strong capabilities in clinical trials, population health data, and real-world evidence, high levels of trust, transparency, and regulatory maturity and last but not least a proven ability to scale innovation within public healthcare systems
This integration is already visible across the region. SNIPR Biome is advancing CRISPR-based precision antimicrobials, CCIT-DK at Herlev Hospital is translating genome-editing research into clinical practice, and Lund University continues to drive fundamental innovation in gene-editing technologies. Together, these examples illustrate the full spectrum, from academic discovery to clinical translation and commercial development. The Nordics can contribute not only scientific excellence but also models for how advanced therapies are responsibly implemented, evaluated, and made accessible. In this way, Medicon Valley can help ensure that CRISPR medicine evolves in a manner that is clinically meaningful, ethically grounded, and societally sustainable.